...Bayer launched Jaydess low-dose levonorgestrel-releasing intrauterine system in the U.K. as a long-term contraceptive. The product, which costs £69.22...
...company said one device can be used for up to three years. Bayer already markets Jaydess...

...FDA approved 13.5 mg Skyla levonorgestrel-releasing intrauterine device (IUD) to prevent pregnancy for up to 3...
...The company plans to launch the product next month. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Skyla...

...Bayer said its Jaydess low-dose levonorgestrel-releasing intrauterine system was approved under the EU's decentralized procedure as a long-term contraceptive...
...under review in the U.S. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Jaydess ( LCS , low-dose levonorgestrel-releasing intrauterine system...

...releases a constant, low dose of levonorgestrel. Bayer AG (Xetra:BAY), Leverkusen, Germany Product: Jaydess ( LCS...

...of bacterial and fungal pathogens all enhanced HIV-1 transmission compared with control medium. Langerhans cells (LCs...
...Further studies are necessary to identify the receptors for the inflammatory cytokines and pathogens on LCs...

...The LCS symptoms Lung Cancer Subscale (LCS) of the Functional Assessment of Cancer Therapy for Lung...

...The agency twice rejected AZN's requests to use improvement on the Lung Cancer Subscale ( LCS...
...in total LCS score for a minimum of four weeks without interim worsening (see "The LCS...
...of those who received the 250 mg and 500 mg doses, respectively, reported improvements in LCS...

...Scientists reported in Nature Medicine that rat ESC-LCs, derived from rat blastocysts, remained viable and engrafted...